Hillsdale Investment Management Inc. Grows Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Hillsdale Investment Management Inc. increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 0.4% during the 4th quarter, HoldingsChannel reports. The firm owned 68,000 shares of the company’s stock after buying an additional 300 shares during the period. Hillsdale Investment Management Inc.’s holdings in Harmony Biosciences were worth $2,340,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC grew its stake in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the period. KBC Group NV increased its position in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after purchasing an additional 819 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences in the 3rd quarter worth approximately $74,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock worth $80,000 after buying an additional 519 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. HC Wainwright decreased their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Mizuho raised their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences has an average rating of “Buy” and a consensus target price of $53.33.

Harmony Biosciences Price Performance

Shares of Harmony Biosciences stock opened at $35.28 on Friday. The firm has a market cap of $2.02 billion, a PE ratio of 16.72, a PEG ratio of 0.47 and a beta of 0.82. The stock has a 50 day moving average of $36.42 and a 200 day moving average of $35.58. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.11. The firm had revenue of $201.30 million during the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted $0.45 earnings per share. On average, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Sandip Kapadia sold 1,775 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock worth $2,831,679 over the last ninety days. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.